These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32882061)

  • 1. Hyperferritinemia in patients with COVID-19: An opportunity for iron chelation?
    Vlahakos VD; Marathias KP; Arkadopoulos N; Vlahakos DV
    Artif Organs; 2021 Feb; 45(2):163-167. PubMed ID: 32882061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Mediated Hyperferritinemia and Cardiac Arrest: Preliminary Insights.
    VasanthiDharmalingam P; Karuppagounder V; Watanabe K; Karmouty-Quintana H; Palaniyandi SS; Guha A; Thandavarayan RA
    Drug Discov Today; 2021 May; 26(5):1265-1274. PubMed ID: 33493677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?
    Dalamaga M; Karampela I; Mantzoros CS
    Metabolism; 2020 Jul; 108():154260. PubMed ID: 32418885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ferritin and Severe COVID-19, from Clinical Observations to Pathogenic Implications and Therapeutic Perspectives.
    Ruscitti P; Giacomelli R
    Isr Med Assoc J; 2020 Aug; 22(8):516-518. PubMed ID: 33236586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy.
    Perricone C; Bartoloni E; Bursi R; Cafaro G; Guidelli GM; Shoenfeld Y; Gerli R
    Immunol Res; 2020 Aug; 68(4):213-224. PubMed ID: 32681497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?
    Abobaker A
    Eur J Clin Pharmacol; 2020 Nov; 76(11):1619-1620. PubMed ID: 32607779
    [No Abstract]   [Full Text] [Related]  

  • 7. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
    Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
    Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 Infection Dysregulates Host Iron (Fe)-Redox Homeostasis (Fe-R-H): Role of Fe-Redox Regulators, Ferroptosis Inhibitors, Anticoagulants, and Iron-Chelators in COVID-19 Control.
    Naidu SAG; Clemens RA; Naidu AS
    J Diet Suppl; 2023; 20(2):312-371. PubMed ID: 35603834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
    Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cytokine storm and COVID-19.
    Hu B; Huang S; Yin L
    J Med Virol; 2021 Jan; 93(1):250-256. PubMed ID: 32592501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome.
    Rossi M; Piagnerelli M; Van Meerhaeghe A; Zouaoui Boudjeltia K
    Med Hypotheses; 2020 Nov; 144():110242. PubMed ID: 33254548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination.
    Ramatillah DL; Gan SH; Pratiwy I; Syed Sulaiman SA; Jaber AAS; Jusnita N; Lukas S; Abu Bakar U
    PLoS One; 2022; 17(1):e0262438. PubMed ID: 35077495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
    Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
    Front Immunol; 2021; 12():749291. PubMed ID: 34867978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators.
    Habib HM; Ibrahim S; Zaim A; Ibrahim WH
    Biomed Pharmacother; 2021 Apr; 136():111228. PubMed ID: 33454595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
    Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of iron chelation therapy with deferoxamine.
    Cohen A
    Semin Hematol; 1990 Apr; 27(2):86-90. PubMed ID: 2190321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can steroids reverse the severe COVID-19 induced "cytokine storm"?
    Kolilekas L; Loverdos K; Giannakaki S; Vlassi L; Levounets A; Zervas E; Gaga M
    J Med Virol; 2020 Nov; 92(11):2866-2869. PubMed ID: 32530507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
    Abdulrab S; Al-Maweri S; Halboub E
    Med Hypotheses; 2020 Oct; 143():109897. PubMed ID: 32505909
    [No Abstract]   [Full Text] [Related]  

  • 20. Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients.
    Stader F; Battegay M; Sendi P; Marzolini C
    Clin Pharmacol Ther; 2022 Mar; 111(3):579-584. PubMed ID: 34496043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.